Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Sofen, Howard, MD, Smith, Stacy, MD, Matheson, Robert T., MD, Leonardi, Craig L., MD, Calderon, Cesar, PhD, Brodmerkel, Carrie, PhD, Li, Katherine, MS, Campbell, Kim, PhD, Marciniak, Stanley J., MBA, Wasfi, Yasmine, MD, PhD, Wang, Yuhua, PhD, Szapary, Philippe, MD, Krueger, James G., MD, PhD
Published in Journal of allergy and clinical immunology (01.04.2014)
Published in Journal of allergy and clinical immunology (01.04.2014)
Get full text
Journal Article
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Papp, Kim, Dr, Cather, Jennifer C, MD, Rosoph, Les, MD, Sofen, Howard, MD, Langley, Richard G, MD, Matheson, Robert T, MD, Hu, ChiaChi, EdM, Day, Robert M, PhD
Published in The Lancet (British edition) (25.08.2012)
Published in The Lancet (British edition) (25.08.2012)
Get full text
Journal Article